Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 2026

October 14, 2026

Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill

Performance

52-Week Range 1.1% below 52-week high

19.67

12.9952W Low 19.8952W High

1 Week 1.1% below 1-week high

18.521W Low 19.891W High

Takeda Pharmaceutical Company Limited American Depositary Shares (each (TAK) traded between $12.99 and $19.89 over the past 52 weeks and last traded at $19.67, 1.1% below its 52-week high. Over the past week it ranged between $18.52 and $19.89.

Past 12 Months

+5.3%

+3.3%

+15.4%

+12.1%

+25.9%

+40.1%

1W +$0.99

1M +$0.62

3M +$2.62

6M +$2.12

YTD +$4.05

1Y +$5.63

TAK was +40.1% over the past year, +12.1% over six months, +25.9% year to date, +5.3% in the last week.

12 Months vs Market

TAK

+40.1%

DIA

+12.4%

SPY

+14.9%

QQQ

+17.5%

IWM

+11.1%

Over the past 12 months TAK returned +40.1% versus DIA (Dow) +12.4%, SPY (S&P 500) +14.9%, QQQ (Nasdaq 100) +17.5% and IWM (Russell 2000) +11.1%.

Volume & Liquidity 0.96× 3-mo avg

Today 2,827,657 3-mo avg 2.9M

3.3M

2.7M

2.9M

3.0M

YTD

3.0M

TAK most recently traded 2,827,657 shares against a 3-month average daily volume of 2.9M.

More News

September 30, 2026

Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026

September 22, 2026

Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems

September 18, 2026

U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations

September 14, 2026

New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life

September 09, 2026

Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch. ↗

August 31, 2026

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera

August 28, 2026

ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

August 24, 2026

Takeda (TAK) Q1 2026 Earnings Call Transcript ↗

August 07, 2026

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

August 05, 2026

Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track

Takeda Pharmaceutical Q1 Earnings Call Highlights ↗

July 30, 2026

Via MarketBeat

July 30, 2026

Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies

July 16, 2026

Takeda and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal Products

July 12, 2026

Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO

June 24, 2026

New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1

June 15, 2026

Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations

June 11, 2026

U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease

June 09, 2026

Attorneys at Hagens Berman Announce $474M Win in Amitiza Jury Trial Against Takeda

May 18, 2026

From Hagens Berman

Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results

Takeda Pharmaceutical Q4 Earnings Call Highlights ↗

May 15, 2026

Via MarketBeat

May 13, 2026

Novavax (NVAX) Q2 2025 Earnings Transcript ↗

May 06, 2026

Why Did Axsome Therapeutics Stock Hit Another Record High Today? ↗

May 04, 2026